Clinical trials
Prostate Cancer Metastatic Disease clinical trials
Below are recruiting prostate cancer metastatic disease clinical trials, each written for real people, not researchers. We’re tracking 605 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06439888RecruitingPhase 1/Phase 2
Immune cells plus radiation for limited-stage cancer spread
This trial tests whether giving immune-supporting cells (lymphocytes) alongside focused radiation (SBRT) can help control limited cancer spread. People with 1 to 5 small tumors that can all be radiated within two weeks may be eligible.
LyonAges 18 years+ - NCT07617272RecruitingPhase 2
Testing a drug to shrink high-risk prostate cancer before surgery
This trial tests whether a hormone-blocking drug called darolutamide can shrink aggressive prostate cancer before surgery. Researchers will also use a special blood test to predict who benefits most from the treatment.
GothenburgAges 18 years+ - NCT07253987Recruiting
Cancer Survivors Program for Breast or Prostate Cancer
This study offers a program to help people who have completed their main treatment for early-stage breast or prostate cancer. It focuses on follow-up and support during survivorship, and you are still eligible if you are on certain maintenance therapies like hormone therapy.
BrnoAges 18 years+ - NCT07226986RecruitingPhase 1/Phase 2
Study of AMO959 with Lutetium-177 and ARPI for prostate cancer
This trial tests a new combination therapy for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. It combines an experimental drug (AMO959) with a targeted radiation treatment (Lutetium-177) and a standard hormone therapy to see if it helps control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT07723248RecruitingPhase 3
Oral Rinzimetostat for Advanced Prostate Cancer After Abiraterone
This study tests an experimental pill called rinzimetostat (ORIC-944) for men with advanced prostate cancer that has spread and stopped responding to abiraterone. It may offer a new option if you have not had many other treatments yet.
Coral Springs, FloridaAges 18 years+ - NCT07621692RecruitingPhase 1
New radioactive therapy for advanced prostate cancer
This is an early-stage trial testing a new radioactive treatment (161Tb-PSMA) for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The treatment targets cancer cells using a radioactive metal that may be more effective than older similar treatments.
TaipeiAges 20 years+ - NCT07549256RecruitingPhase 2
Cannabidiol for pain relief in advanced prostate cancer
This trial tests a cannabis-derived medicine called cannabidiol (CBD) for pain relief in men with advanced prostate cancer that has stopped responding to standard treatments. The goal is to see if CBD can help reduce pain when other options have been exhausted.
GistrupAges Any age - NCT06943495RecruitingPhase 1
Personalized vs. standard dose of a targeted therapy for prostate cancer
This trial compares two ways of giving a radioactive drug (177Lu-PSMA-617) designed to find and destroy prostate cancer cells. It tests whether adjusting the dose based on your individual tumor’s activity works better than a fixed standard dose.
Québec, QuebecAges 18 years+ - NCT05983432RecruitingPhase 1
Study of BL-B01D1 for advanced lung and other solid tumors
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT06965192Recruiting
Visual tools for cancer surgeon decision-making
This trial tests visual tools to help surgeons make better decisions for patients with early-stage prostate or kidney cancer. It may help you and your doctor choose the best treatment.
Chapel Hill, North CarolinaAges 18 years+ - NCT07711002RecruitingPhase 3
Saruparib with standard therapy for metastatic hormone-sensitive prostate cancer
This trial tests a new drug called saruparib, which may help keep prostate cancer from growing. It is for men whose cancer has spread and who have already received certain treatments. The study combines saruparib with a standard hormone therapy to see if it works better than the hormone therapy alone.
Hot Springs, ArkansasAges 18 years+ - NCT07503808RecruitingPhase 1
IDE034 for advanced solid tumors with B7-H3 or PTK7
This study tests a new drug called IDE034 for people with advanced solid tumors that have certain markers (B7-H3 and PTK7). The drug may help by targeting these markers on cancer cells, and the study checks if it is safe and effective.
Denver, ColoradoAges 18 years+ - NCT05534646RecruitingPhase 2
Carotuximab plus hormone therapy for advanced prostate cancer
This trial tests a new drug called carotuximab given with a standard hormone therapy (apalutamide or enzalutamide) for men with prostate cancer that has stopped responding to current hormone treatments. The goal is to see if this combination can slow the cancer's growth and lower PSA levels.
Duarte, CaliforniaAges 18 years+ - NCT05000294RecruitingPhase 1/Phase 2
Atezolizumab plus tivozanib for hard-to-treat “cold” cancers
This early-stage study tests whether combining atezolizumab and tivozanib can shrink advanced, hard-to-treat cancers that do not strongly activate the immune system (“immunologically cold”). It is for people whose cancer has already been treated or has no good standard options.
Gainesville, FloridaAges 18–99 - NCT05668962RecruitingPhase 2
Study selpercatinib plus I-131 for RET thyroid cancer that cannot take iodine
This trial tests whether combining a targeted pill (selpercatinib) with a radioactive iodine dose (I-131) can shrink thyroid cancer that has spread and no longer responds to radioactive iodine. It is for RET fusion–positive (genetically driven) thyroid cancers where the cancer cannot reliably absorb iodine anymore.
Washington D.C., District of ColumbiaAges 12 years+ - NCT06594926RecruitingPhase 2
Bipolar androgen therapy for prostate cancer without metastases
This trial tests a treatment called bipolar androgen therapy for men with prostate cancer that has not spread to other parts of the body and is still growing despite taking darolutamide. The goal is to see if this therapy can help control the cancer.
Garran, Australian Capital TerritoryAges 18 years+ - NCT06549465RecruitingPhase 2
Ac-225 rosopatamab for PSMA-positive castration-resistant prostate cancer
This trial tests a radioactive drug (Ac-225 rosopatamab tetraxetan) that targets a protein called PSMA on prostate cancer cells. It is for patients whose cancer has stopped responding to hormone therapy and has spread to other parts of the body.
San Diego, CaliforniaAges 18 years+ - NCT06282588RecruitingPhase 2/Phase 3
Advanced imaging-guided treatment for high-risk prostate cancer
This trial uses a special PET scan (PSMA PET/CT) and a genetic test (Decipher) to decide the best treatment for high-risk prostate cancer that hasn't spread outside the pelvis. You'll receive standard radiation and hormone therapy, possibly with an extra drug (darolutamide).
Wilrijk, AntwerpAges 18 years+ - NCT04212715RecruitingPhase 2
Extra radiation boost for high-risk prostate cancer
This Phase 2 study tests a treatment plan that uses standard focused radiation to the prostate, plus an extra “boost” delivered inside the prostate. It may help improve control of high-risk prostate cancer, especially by aiming radiation more precisely.
RiyadhAges 18–99 - NCT07142551RecruitingPhase 2
Testosterone priming with darolutamide for metastatic prostate cancer
This trial tests whether giving a high dose of testosterone before standard hormone therapy can help the treatment work longer for men with prostate cancer that has spread. You would receive testosterone injections for a short time, then a hormone blocker (darolutamide) along with continued testosterone shots.
Baltimore, MarylandAges 18 years+ - NCT06126731RecruitingPhase 1/Phase 2
Antibiotics plus enzalutamide for advanced prostate cancer
This trial tests whether adding specific antibiotics (amoxicillin, metronidazole, vancomycin, ciprofloxacin) to enzalutamide can help treat advanced prostate cancer that has stopped responding to other treatments. It aims to see if changing gut bacteria can make the cancer therapy work better.
BellinzonaAges 18 years+ - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Phoenix, ArizonaAges 18 years+ - NCT07690917Recruiting
New PET scanner study for people with cancer
This study tests a new PET scanner that may give clearer or more detailed pictures of cancer. It is for people who are already scheduled for a PET-CT scan at Memorial Sloan Kettering, and it could help doctors see cancer more precisely.
Basking Ridge, New JerseyAges 18 years+ - NCT06922318RecruitingPhase 2
Combined suppression of MYC for advanced prostate cancer
This trial tests a new combination of drugs (ZEN-3694 and enzalutamide) for men with advanced prostate cancer that has stopped responding to standard hormonal treatments. It aims to see if this combination can help slow or stop the cancer from growing.
Baltimore, MarylandAges 18 years+
Hear when a new Prostate Cancer Metastatic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer metastatic disease?
- Yes. Clin2 currently lists 605 recruiting prostate cancer metastatic disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer metastatic disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer metastatic disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Castration-resistant Prostate Cancer
- Metastatic Prostate Cancer
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- Metastatic Castration-Resistant Prostate Cancer Patients
- Non-metastatic Castration-resistant Prostate Cancer
- Metastatic Breast Cancer
- Metastatic Colorectal Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.